**Supplementary Table 1: The DE&I deficit in cardiovascular research**

|  |  |  |  |
| --- | --- | --- | --- |
| Study  | Sample size | Male (%)  | Race (%) |
| FLAVOUR (82)Koo et al. 2022 *NewEngJMed*  | N= 1682 | 71%\* | Not reported |
| IRONMAN (83)P. R. Kalra et al. 2022 The Lancet  | N= 1164 | 72%\* | White: 90%Black: 2%Asian: 6%Other <1% |
| ADVOR (84)Mullens et al. 2022 *NewEngJMed*  | N= 519 | 63%\* | White: 99% |
| DIAMOND (85)Butler et al. 2022*EurHeartJ*  | N= 878 | 73%\* | White: 98%Hispanic or Latino:13% |
| PACMAN-AMI (86)Raber et al. 2022*JAMA*  | N= 300  | 80%\* | Not reported |

Key: \* indicates that only Male and Female were reported

Source: https://www.acc.org/Latest-in-Cardiology/Articles/2022/12/15/01/2022-Top-Clinical-Trials-and-Journal-Scans

**References:**

82. Koo B-K, Hu X, Kang J, Zhang J, Jiang J, Hahn J-Y, et al. Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. N Engl J Med. 2022;387(9):779-89.

83. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022;400(10369):2199-209.

84. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022;387(13):1185-95.

85. Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362-73.

86. Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. JAMA. 2022;327(18):1771.